Back to first-pass browser

First-pass extracted concept

fibrinogen

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Fibrinogen is highlighted as a key contextual component in the review's discussion of breast tumorigenesis and fibrinolytic physiology.

Source 1DOIPubMed

What problem it solves

It provides the biological framework for the review's proposed link between hormone exposure and malignant-cell immune escape.

Source 1DOIPubMed

What it does not solve

The abstract does not define a specific intervention, assay, or engineered use for fibrinogen.

Source 1DOIPubMed

Evidence Snippets

Inconsistencies in existing theories highlight the need for further detailed research on the relationship between hormone exposure and breast tumorigenesis, with particular emphasis on fibrinogen and its components in the context of this review.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1hormone risk comparisonsupports2025Source 1DOIPubMed

The review states that breast-cancer risk is greater when estrogen replacement is combined with progesterone, whereas isolated estrogen use does not represent a significant risk.

Claim 2proposed mechanismsupports2025Source 1DOIPubMed

The review concludes that free estrogen and fibrinogen-related proteins including FGL1 and FGL2 play a role in failure of immune containment of malignant cells in breast cancer.

Claim 3review hypothesis scopesupports2025Source 1DOIPubMed

The review argues that inconsistencies in estrogen-centered theories of breast tumor initiation motivate a new hypothesis emphasizing fibrinogen and related components.

Claim 4therapeutic research implicationsupports2025Source 1DOIPubMed

The review presents fibrinogen-related immune-containment failure as opening another field of therapeutic research for breast cancer.